OncoBeta ® GmbH Named Among '30 Ethical Companies of the Year 2019' by The Silicon Review Magazine

MUNICH, Germany - April 5, 2019 - EntSun -- April 05, 2019; Garching near Munich, Germany - OncoBeta® GmbH, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancer (NMSC) proudly announced today that the Silicon Review Magazine has named it among the 30 Ethical Companies of the Year 2019.

"The Silicon Review 30 Ethical Companies of the Year 2019 program identifies companies that are not only financially successful but also are among the most ethical. Winning a spot on this list indicates the company has distinguished itself as an ethically-driven organization," said Sreshtha Banerjee, Editor-in-Chief of The Silicon Review Magazine. The publication has selected OncoBeta® GmbH based on its culture of learning, strong ethical leadership, integrity and fairness, and moreover, the ability to maintain their global business conduct.

"We adhere to a high level of core values in our doings, focusing on providing the best products possible for patients and physicians." states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH "It is an honor for us to be recognized and featured in this prominent publication for our work ethics and principles that govern our behavior on how we conduct our business."

With the patient in focus, OncoBeta works enthusiastically with medical, scientific, and industrial partners as well as local and national authorities to make his personalized, painless and non-invasive Rhenium-SCT® therapy accessible to patients all over the world.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.

More on EntSun News

• Voting Opens Tonight for the 2025 Spin Awards Honoring Excellence in Christian Gospel Radio
• Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce
• Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
• NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
• "The Grateful Dead — 60 Years in San Francisco" - Pantheon Media Launches New Podcast Series and Interactive "Hit Replay" App

View the complete list of the Top 30 Ethical Companies 2019 in the digital Silicon Review magazine here:
https://thesiliconreview.com/magazines/magazine_profile.php?id=181&page=3

Read Silicon Review's exclusive interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH here:
https://thesiliconreview.com/magazines/the-pioneers-and-innovators-in-the-epidermal-radioisotope-therapy-sector-oncobeta-gmbh/

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium- SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium- SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.

More on EntSun News

• Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
• Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
• SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
• From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
• 'Unity Through Christ Music Festival' coming to Detroit Saturday August 9, 2025

Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

Find out more about the Rhenium-SCT® at https://www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

Facebook: https://www.facebook.com/OncoBeta/

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

END